191 related articles for article (PubMed ID: 23901083)
1. A targeted and adjuvanted nanocarrier lowers the effective dose of liposomal amphotericin B and enhances adaptive immunity in murine cutaneous leishmaniasis.
Daftarian PM; Stone GW; Kovalski L; Kumar M; Vosoughi A; Urbieta M; Blackwelder P; Dikici E; Serafini P; Duffort S; Boodoo R; Rodríguez-Cortés A; Lemmon V; Deo S; Alberola J; Perez VL; Daunert S; Ager AL
J Infect Dis; 2013 Dec; 208(11):1914-22. PubMed ID: 23901083
[TBL] [Abstract][Full Text] [Related]
2. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
3. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.
Abu Ammar A; Nasereddin A; Ereqat S; Dan-Goor M; Jaffe CL; Zussman E; Abdeen Z
Drug Deliv Transl Res; 2019 Feb; 9(1):76-84. PubMed ID: 30484256
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Alavijeh M; Silva-Pedrosa R; Antunes S; Mauricio I; Murdan S; Croft SL
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):223-228. PubMed ID: 29673889
[TBL] [Abstract][Full Text] [Related]
5. Leishmanicidal activity of amphotericin B encapsulated in PLGA-DMSA nanoparticles to treat cutaneous leishmaniasis in C57BL/6 mice.
de Carvalho RF; Ribeiro IF; Miranda-Vilela AL; de Souza Filho J; Martins OP; Cintra e Silva Dde O; Tedesco AC; Lacava ZG; Báo SN; Sampaio RN
Exp Parasitol; 2013 Oct; 135(2):217-22. PubMed ID: 23891944
[TBL] [Abstract][Full Text] [Related]
6. Poloxamer 407 (Pluronic(®) F127)-based polymeric micelles for amphotericin B: In vitro biological activity, toxicity and in vivo therapeutic efficacy against murine tegumentary leishmaniasis.
Mendonça DV; Lage LM; Lage DP; Chávez-Fumagalli MA; Ludolf F; Roatt BM; Menezes-Souza D; Faraco AA; Castilho RO; Tavares CA; Barichello JM; Duarte MC; Coelho EA
Exp Parasitol; 2016 Oct; 169():34-42. PubMed ID: 27427166
[TBL] [Abstract][Full Text] [Related]
7. Relation between Skin Pharmacokinetics and Efficacy in AmBisome Treatment of Murine Cutaneous Leishmaniasis.
Wijnant GJ; Van Bocxlaer K; Yardley V; Harris A; Murdan S; Croft SL
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263075
[TBL] [Abstract][Full Text] [Related]
8. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
9. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
[TBL] [Abstract][Full Text] [Related]
10. Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.
Mehrizi TZ; Ardestani MS; Khamesipour A; Hoseini MHM; Mosaffa N; Anissian A; Ramezani A
J Mater Sci Mater Med; 2018 Jul; 29(8):125. PubMed ID: 30056571
[TBL] [Abstract][Full Text] [Related]
11. Activity of Amphotericin B-Loaded Chitosan Nanoparticles against Experimental Cutaneous Leishmaniasis.
Riezk A; Van Bocxlaer K; Yardley V; Murdan S; Croft SL
Molecules; 2020 Sep; 25(17):. PubMed ID: 32887341
[TBL] [Abstract][Full Text] [Related]
12. An amphotericin B-based drug for treating experimental Leishmania major infection.
Corware KD; Rogers M; Teo I; Müller I; Shaunak S
Trans R Soc Trop Med Hyg; 2010 Nov; 104(11):749-50. PubMed ID: 20850850
[TBL] [Abstract][Full Text] [Related]
13. Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B.
Wijnant GJ; Van Bocxlaer K; Fortes Francisco A; Yardley V; Harris A; Alavijeh M; Murdan S; Croft SL
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30082295
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the in vivo leishmanicidal activity of amphotericin B emulgel: An alternative for the treatment of skin leishmaniasis.
Pinheiro IM; Carvalho IP; de Carvalho CE; Brito LM; da Silva AB; Conde Júnior AM; de Carvalho FA; Carvalho AL
Exp Parasitol; 2016 May; 164():49-55. PubMed ID: 26902606
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and
Iman M; Huang Z; Alavizadeh SH; Szoka FC; Jaafari MR
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630182
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the in vitro and in vivo antileishmanial activity of a chloroquinolin derivative against Leishmania species capable of causing tegumentary and visceral leishmaniasis.
Soyer TG; Mendonça DVC; Tavares GSV; Lage DP; Dias DS; Ribeiro PAF; Perin L; Ludolf F; Coelho VTS; Ferreira ACG; Neves PHAS; Matos GF; Chávez-Fumagalli MA; Coimbra ES; Pereira GR; Coelho EAF; Antinarelli LMR
Exp Parasitol; 2019 Apr; 199():30-37. PubMed ID: 30817917
[TBL] [Abstract][Full Text] [Related]
17. Lipid nanoparticles for amphotericin delivery in the treatment of American tegumentary leishmaniasis.
de Souza RM; Maranhão RC; Tavares ER; Filippin-Monteiro FB; Nicodemo AC; Morikawa AT; Kanashiro EHY; Amato VS
Drug Deliv Transl Res; 2020 Apr; 10(2):403-412. PubMed ID: 31701487
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of
Rebouças-Silva J; Tadini MC; Devequi-Nunes D; Mansur AL; S Silveira-Mattos P; I de Oliveira C; R Formiga F; Berretta AA; Marquele-Oliveira F; Borges VM
Int J Nanomedicine; 2020; 15():8659-8672. PubMed ID: 33177824
[TBL] [Abstract][Full Text] [Related]
19. Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.
Corware K; Harris D; Teo I; Rogers M; Naresh K; Müller I; Shaunak S
Biomaterials; 2011 Nov; 32(31):8029-39. PubMed ID: 21807409
[TBL] [Abstract][Full Text] [Related]
20. Appraisal of a Leishmania major strain stably expressing mCherry fluorescent protein for both in vitro and in vivo studies of potential drugs and vaccine against cutaneous leishmaniasis.
Calvo-Álvarez E; Guerrero NA; Alvarez-Velilla R; Prada CF; Requena JM; Punzón C; Llamas MÁ; Arévalo FJ; Rivas L; Fresno M; Pérez-Pertejo Y; Balaña-Fouce R; Reguera RM
PLoS Negl Trop Dis; 2012; 6(11):e1927. PubMed ID: 23209866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
